Home Tags MMAE

Tag: MMAE

Seattle Genetics to Co-develop Tisotumab Vedodin with Genmab for the Treatment...

Genmab, an international biotechnology company headquartered in Copenhagen, Denmark, and Seattle Genetics, confirmed that Seattle Genetics has exercised its option to co-develop tisotumab vedotin. The...

Brentuximab Vedotin Approved by Health Canada for Post-ASCT Consolidation Treatment of...

Health Canada, the federal department responsible for helping Canadians maintain and improve their health, has issued a non-conditional marketing authorization for use of brentuximab...
Featured Image: Nyhavn, Copenhagen, Denmark. Courtesy: © Fotolia. Used with permission.

Glembatumumab vedotin Shows Encouraging anti-tumor Activity Checkpoint Inhibitor-refractory Metastatic Melanoma

Results from a phase II trial presented in a poster at the annual meeting of the European Society of Medical Oncology, held in Copenhagen,...

European Commission Approves Brentuximab Vedotin for Consolidation Treatment in Post-Transplant Hodgkin...

The European Commission (EC) has extended the current conditional marketing authorization of brentuximab vedotin (Adcetris®/Seattle Genetics/Takeda Oncology) and approved the drug for the treatment of...

Clinical Phase I Data for ASG-15ME and Enfortumab Vedotin (ASG-22ME) Indicates...

Clinical data for ASG-15ME and Enfortumab vedotin, also known as ASG-22ME and ASG-22M6E,  presented at the American Society of Clinical Oncology's (ASCO) 51st Annual Meeting held June...

Studies Show Glembatumumab Vedotin to be Effective in a Wide Range...

During the annual meeting of the American Association for Cancer Research (AACR) being held  April 16 - 20, 2016 in New Orleans, LA, Celldex...

Glembatumumab Vedotin in Patients with Metastatic gpNMB-overexpressing Triple-negative Breast Cancer

Researchers have, in the last decades, made major advances in the development of therapies for breast cancer by identifying key markers known to drive...

Improving Hodgkin Lymphoma Treatment: Brentuximab Vedotin Data Supports Foundation of...

Final pivotal trial results in relapsed/refractory Hodgkin lymphoma (HL) demonstrate durable remissions lasting more than five years after brentuximab vedotin (Adcetris®; Seattle Genetics) monotherapy.  Oral...

First of Two Planned Trials Combining Brentuximab Vedotin and Nivolumab Start...

Seattle Genetics, a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer, has initiated a phase 1/2...

Analysis of Phase III AETHERA Data Demonstrates Brentuximab Vedotin Consolidation Therapy...

Several new analysis of Phase III data from the AETHERA trial (NCT01100502) demonstrate that brentuximab vedotin (Adcetris®; Seattle Genetics) consolidation therapy significantly extends progression-free...